Skip to content

The clinical study of yiqi fixation treatment for allergic rhinitis

The clinical study of yiqi fixation treatment for allergic rhinitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014416
Enrollment
Unknown
Registered
2018-01-12
Start date
2018-02-01
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Treatment group:Yiqigubiao granule + Loratadine Tablets
control group:Yiqi Gubiao granule placebo + Loratadine Tablets

Sponsors

Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet The diagnostic criteria of allergic rhinitis acute phase; 2. aged 18~65 years; 3. The total course of disease was more than one year, and the acute attack was less than 72 hours; 4. The subjects signed informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with upper respiratory tract infection, eosinophilia, vasomotor rhinitis, and nasal polyps have similar symptoms of allergic rhinitis; (2) the drug who has been used in the treatment of allergic rhinitis within one week of this disease; (3) patients with pneumonia, bronchitis and asthma; (4) women in pregnancy and lactation; (5) patients with severe primary heart, liver, lung, kidney, blood diseases and diabetes or serious diseases that affect their survival; (6) The mental or behavioral disorders because they cannot give full informed consent; (7) The suspected alcohol and drug abuse history; (8) According to the researcher's judgment, can reduce the possibility of the group or other lesions into the group is complicated, such as work environment change often causes lost condition; (9) To allergies, as of two or more drugs or food allergy, or known allergy to the drug ingredients; (10) The other is to participate in the clinical trial subjects.

Design outcomes

Primary

MeasureTime frame
sneeze;Runny nose;nasal obstruction;Nasal itching;Routine blood test;Urine routine test;electrocardiogram;liver function test;Renal function test;IL-6;TNF;total IgE;adverse events;Clinical signs: the color of the nasal mucosa, the degree of edema, the change of nasal turbinate.;

Secondary

MeasureTime frame
Sweating, chill, itching, itching;

Countries

China

Contacts

Public ContactZhang Zhongde

Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

doctorzzd99@163.com+86 020-81887233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026